J&J may face $1bn fine for mis-selling

Share

HEALTHCARE giant Johnson & Johnson (J&J) faces a fine of about $1bn (£609m) to settle a US probe into whether it illegally marketed its high-selling antipsychotic drug Risperdal.

Such a fine would be one of the biggest penalties imposed on a pharmaceutical company for marketing drugs for non-approved uses. The US government has been investigating J&J since 2004 over Risperdal sales, the Wall Street Journal reported.